Figure 4From: Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphomaAnti-human CCR7 mAb reduces tumor cell infiltration in bone marrow and spleen in the subcutaneous model of the MCL. One million cells from spleen and bone marrow were harvested and incubated with anti-human-CD20 mAb and the respective irrelevant isotype control. Then, the number of xenografted Granta-519 cells migrated to bone marrow and spleen in control mice (grey bar) and treated mice (black bar) was quantified. The mean ± SE is shown. P-values refer to the differences of infiltration in tissues from PBS- and anti-CCR7 mAb-treated mice.Back to article page